nortriptyline / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 72 Diseases   9 Trials   9 Trials   809 News 


«12345678910»
  • ||||||||||  Journal:  Magnetic Particle Spray Mass Spectrometry. (Pubmed Central) -  Mar 29, 2024   
    MPS-MS opens a new line of developments in the association of sample preparation with ambient ionization. New sorbents, device configurations, and physical and chemical conditions can also be analyzed for the analysis of many other analytes in different samples.
  • ||||||||||  Trintellix (vortioxetine) / Lundbeck, Takeda
    Review, Journal:  Post-Stroke Depression in Older Adults: An Overview. (Pubmed Central) -  Feb 24, 2024   
    High-quality RCTs recruiting large samples of older adults are needed in order to better manage PSD in this population. In addition, adequate screening and diagnosis instruments, with reliable timing of evaluation, should be applied.
  • ||||||||||  Chantix (varenicline) / Pfizer
    Review, Journal:  Psychopharmacology of smoking cessation medications: focus on patients with mental health disorders. (Pubmed Central) -  Feb 1, 2024   
    Nortriptyline and Clonidine are second-line treatments used when the first-line treatments are not effective or are contraindicated...Careful consideration of the risks and benefits of using smoking cessation medications is necessary, and treatment plans must be tailored to individual patients' needs. Monitoring symptoms and medication regimens is essential to ensure optimal treatment outcomes.
  • ||||||||||  Journal:  Challenging Case: A Multidisciplinary Approach to Demystifying Chronic Sleep Impairment in an Infant with a Complex Medical and Behavioral Profile. (Pubmed Central) -  Jan 30, 2024   
    At this time, an infant mental health consultant met with a sleep psychologist on the family's behalf to support family in considering systematic desensitization therapy to increase tolerance to wearing his BiPAP mask, as well as other behavioral and sleep hygiene strategies, which were tried on several occasions and again, resulted in limited improvement in functioning.At 19 months, X's multidisciplinary team reconsidered a night terror diagnosis after a failed trial of clonazepam and pursued a differential diagnosis of periodic limb movement disorder (PLMD)...He had been on iron supplementation since age 6 months and received an iron infusion at 22 months because of persistently low ferritin levels and PLMD in sleep.At 24 months, X was briefly trialed on levetiracetam...At 25 months, an evaluation with a movement disorder physiatrist resulted in a diagnosis of nocturnal paroxysmal dystonia, and he was started on baclofen, which has provided some, but not complete relief to nighttime symptoms...What are the implications of chronic sleep deprivation and stress on the behavior and development of infant with X's profile? What are important psychosocial considerations because it relates to children with medical complexity (CMC), particularly for X and his family to support caregiver, family, and X's quality of life and overall well-being?
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Journal:  Activation of NOP receptor increases vulnerability to stress: role of glucocorticoids and CRF signaling. (Pubmed Central) -  Jan 25, 2024   
    These findings underscore the intricate and region-specific mechanisms governing DA uptake in astrocytes, emphasizing the need for continued exploration to unravel the nuanced dynamics of astrocytic involvement in the DA tripartite synapse. Present findings suggest that NOP agonists increase vulnerability to depression by hyperactivating the HPA axis and then increasing stress circulating hormones and CRF receptor signaling.
  • ||||||||||  lithium carbonate ER / Generic mfg.
    Journal:  Drugs for depressionr. (Pubmed Central) -  Dec 26, 2023   
    The risk for these adverse events from paroxetine was comparable to the alternative medications. No abstract available
  • ||||||||||  Chantix (varenicline) / Pfizer
    Review, Journal:  Obstructive Sleep Apnea and Smoking Increase the Risk of Cardiovascular Disease: Smoking Cessation Pharmacotherapy. (Pubmed Central) -  Dec 23, 2023   
    There are few existing data examining how pharmacological treatment, such as nicotine replacement therapy (NRT), bupropion, and varenicline, affect smokers suffering with OSA and especially their cardiovascular effects...Studies on second-line medication (nortriptyline, clonidine, cytisine) are even more limited...Smokers should receive personalized treatment during their quitting attempts according to their individual needs and problems, including OSA. Future studies are needed in order to evaluate the efficacy and safety of smoking cessation medications in OSA patients.
  • ||||||||||  Chantix (varenicline) / Pfizer
    Journal:  Smoking cessation and its significant role in the Indian scenario. (Pubmed Central) -  Dec 5, 2023   
    Every healthcare professional has a duty to help smokers stop using tobacco, and the intervention should be both therapeutic and diagnostic. Combining behavioral and social support yields the best results, along with pharmacotherapy whenever needed.
  • ||||||||||  nortriptyline / Generic mfg.
    Trial completion date, Trial primary completion date:  Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments (clinicaltrials.gov) -  Nov 29, 2023   
    P2,  N=400, Recruiting, 
    Combining behavioral and social support yields the best results, along with pharmacotherapy whenever needed. Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Oct 2023 --> Oct 2024
  • ||||||||||  Retrospective data, Journal:  The Impact of Non-opioid Analgesic Usage on Total Opioid Load During Traumatic Brain Injury Rehabilitation: A Retrospective Study. (Pubmed Central) -  Nov 13, 2023   
    This study aimed to determine the association between non-opioid analgesic use and total opioid load, as measured using morphine milligram equivalents (MMEs), during inpatient rehabilitation for traumatic brain injury...Non-opioid medications that were reviewed in the study included acetaminophen, amitriptyline, baclofen, diclofenac, gabapentin, ibuprofen, lidocaine, methocarbamol, nortriptyline, and pregabalin...Results also showed that the mere presence of methocarbamol (regardless of daily or total dosage) had a significant effect on the ?MME. Conclusions Based on these findings, physicians may want to consider prescribing acetaminophen, gabapentin, or methocarbamol for patients admitted for inpatient rehabilitation following traumatic brain injury who require high amounts of opioids.
  • ||||||||||  amitriptyline / Generic mfg., nortriptyline / Generic mfg.
    Biomarker, Journal:  Pharmacogenomic testing for CYP2C19 and CYP2D6 in cyclic vomiting syndrome. (Pubmed Central) -  Nov 13, 2023   
    Larger prospective studies to evaluate the clinical impact of pharmacogenomic testing in CVS are needed. This has the potential to optimize clinical management, predict ADRs and allow for personalized therapy.
  • ||||||||||  nortriptyline / Generic mfg.
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  PeCon: Pediatric Concussion Outcomes (clinicaltrials.gov) -  Nov 7, 2023   
    P4,  N=8, Active, not recruiting, 
    This has the potential to optimize clinical management, predict ADRs and allow for personalized therapy. Enrolling by invitation --> Active, not recruiting | N=100 --> 8 | Trial completion date: Aug 2025 --> Mar 2024 | Trial primary completion date: Feb 2025 --> Jun 2023
  • ||||||||||  lithium carbonate ER / Generic mfg.
    Biomarker, Trial primary completion date:  ONR: RCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT) (clinicaltrials.gov) -  Oct 18, 2023   
    P4,  N=600, Active, not recruiting, 
    Treatment with gabapentin and antidepressants should be considered in patients with chronic pruritus unresponsive to conventional treatment. Trial primary completion date: Jan 2024 --> Apr 2024
  • ||||||||||  Was It Serotonin Syndrome? (Exhibit Hall) -  Aug 23, 2023 - Abstract #ASA2023ASA_4641;    
    She was subsequently admitted for Neuro workup, which was unremarkable. Could this have been serotonin syndrome?
  • ||||||||||  Viibryd (vilazodone) / AbbVie
    Journal:  Drugs for anxiety disorders. (Pubmed Central) -  Aug 3, 2023   
    Could this have been serotonin syndrome? No abstract available
  • ||||||||||  nortriptyline / Generic mfg.
    Journal:  Cyclodextrin's Effect on Permeability and Partition of Nortriptyline Hydrochloride. (Pubmed Central) -  Jul 29, 2023   
    The findings of this study revealed similar trends in the 1-octanol/buffer 6.8 pH distribution and permeability through the PermeaPad barrier in the presence of CDs. These results were attributed to the determinative role of the distribution coefficient (serving as a descriptor) in permeation through the PermeaPad barrier modeling the lipophilic nature of biological barriers.
  • ||||||||||  verapamil / Generic mfg., topiramate / Generic mfg., nortriptyline / Generic mfg.
    Review, Journal:  Management of Migraine-Associated Vestibulocochlear Disorders. (Pubmed Central) -  Jul 25, 2023   
    We have included an algorithm that outlines a suggested approach for addressing these symptoms, taking into account our clinical observations. Greater recognition and understanding of migraine and its related vestibular and cochlear symptoms are needed to ensure the appropriate diagnosis and treatment of affected patients.
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    Journal:  Harlequin syndrome. (Pubmed Central) -  Jul 17, 2023   
    He was started on erenumab for migraine prophylaxis and was given sumatriptan for abortive therapy following which his headaches improved. The patient was diagnosed with idiopathic left Horner's syndrome and his migraines with autonomic dysfunction would present with unilateral flushing opposite to the site of Horner's presenting as Harlequin syndrome [1, 2].
  • ||||||||||  Journal:  Comparison table: Some drugs for migraine prevention in adults. (Pubmed Central) -  Jun 6, 2023   
    The patient was diagnosed with idiopathic left Horner's syndrome and his migraines with autonomic dysfunction would present with unilateral flushing opposite to the site of Horner's presenting as Harlequin syndrome [1, 2]. No abstract available
  • ||||||||||  Journal:  Drugs for migraine. (Pubmed Central) -  Jun 6, 2023   
    No abstract available No abstract available
  • ||||||||||  amitriptyline / Generic mfg.
    Toxicities With Polypharmacy: A Case of Amitriptyline Toxicity (Hall B Foyer, Exhibition Level Moscone South) -  May 17, 2023 - Abstract #APA2023APA_1111;    
    Her combined amitriptyline and nortriptyline level on bloodwork drawn the day of the appointment was 300 mcg/mL, 50 mcg over the high end of the therapeutic range...In this patient, we found an interaction between amitriptyline and bupropion at the CYP 2D6 enzyme, which caused the amitriptyline level to be elevated. Her older age also made her more sensitive to anticholinergic side effects, which were the most prevalent in this patient.
  • ||||||||||  (Dis)Trust Your Gut: Serotonin and the GI Tract (Hall B Foyer, Exhibition Level Moscone South) -  May 17, 2023 - Abstract #APA2023APA_569;    
    Current regimen of 100 mg desvenlafaxine and 10 mg aripiprazole daily...This spurred multiple subsequent research studies regarding the GI tract of animals and thus, humans, and the interplay between serotonin, gut health, and ipso facto mental health. Here we outline several of these subsequent papers that outline the multiple gut microbe strains that have purported relationships with serotonin, and discuss their strengths and shortcomings in an ultimate forecast of research to come in a growing field of the relationships between gut health and mental health.
  • ||||||||||  nortriptyline / Generic mfg., escitalopram / Generic mfg.
    Trial completion, Enrollment change:  ADepT-PD: Antidepressants Trial in Parkinson's Disease (clinicaltrials.gov) -  May 6, 2023   
    P3,  N=52, Completed, 
    ClinicalTrials.gov Identifier: NCT03548675. Recruiting --> Completed | N=408 --> 52
  • ||||||||||  nortriptyline / Generic mfg.
    Journal:  Clinical characteristics associated with relapse two years after electroconvulsive therapy for major depression. (Pubmed Central) -  Mar 21, 2023   
    Depressed patients with psychotic features, with higher symptom severity and without medication resistance prior to ECT have a significantly decreased risk of relapse after successful ECT. A sustained remission rate of 50% over two years in patients with severe major depression who were treated with nortriptyline monotherapy after successful ECT is encouraging.
  • ||||||||||  Chantix (varenicline) / Pfizer
    Review, Journal:  Pharmacotherapy in Tobacco Cessation: A Narrative Review. (Pubmed Central) -  Mar 21, 2023   
    A sustained remission rate of 50% over two years in patients with severe major depression who were treated with nortriptyline monotherapy after successful ECT is encouraging. This paper